GLOBAL LIVER INSTITUTE
The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.
This landmark announcement from the White House follows ongoing advocacy efforts, including a letter to President Joe Biden sent by Prevent Cancer Foundation, GLI, and 80 other advocacy groups to establish Cancer Prevention and Early Detection Month.
Maintaining optimal liver health is crucial, given the liver’s pivotal role as a major detoxifying organ. The liver, being a primary filter of toxins and chemicals that pass through the body, is influenced by an individual’s dietary choices.
Our press kit explains the core facts of the GLI, the Resmetirom launch, and why it’s important (especially to patients) to journalists/reporters/the media in a neat, digestible package.
Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It impacts millions worldwide leading to missed opportunities for early intervention and prevention. Studies highlight a concerning gap in identifying patients within the healthcare system who may have fatty liver disease unknowingly. We cannot afford to overlook the silent nature of this and this is why we are advocating for immediate action.
(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the breaking news of the U.S. FDA’s approval for Mirum Pharmaceuticals’ Livmarli to treat cholestasis pruritus in patients 5 and older that have been diagnosed with progressive familial intrahepatic cholestasis (PFIC), a rare, genetic disorder in which bile builds up in the liver.
Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication for nonalcoholic steatosis (NASH). Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
Madrigal Pharmaceuticals celebrates EMA’s validation of the Marketing Authorization Application for Resmetirom, a potential breakthrough therapy for NASH/MASH with liver fibrosis, while eagerly awaiting FDA’s decision, marking significant progress in the fight against liver-related mortality in Europe.
Congress continues to narrowly avert a government shutdown, most recently with yet another Continuing Resolution to extend government funding through later in March.
Please join us on April 18 for a liver cancer care webinar open to patients, caregivers, and health care professionals. Experts will discuss topics relevant to the care and treatment of liver cancer and its symptoms so that patients and providers alike can make informed care decisions.
In February, GLI raised awareness and amplified the patient voice in discussions about transitions in care for rare liver diseases. Here are a few highlights.
Dr. Ufere spoke with GLI about the financial insecurities of patients with chronic liver disease. In her experience, the decision to seek medical care often boils down to affordability, at the end of the day.
